{"servers":[{"server":{"$schema":"https://static.modelcontextprotocol.io/schemas/2025-12-11/server.schema.json","name":"com.midgardfinance/drugs","description":"Obesity and incretin drug trials: weight loss by dose with its estimand, adverse events, catalysts","title":"Midgard Finance drug data","version":"0.1.0","websiteUrl":"https://www.midgardfinance.com/obesity/","remotes":[{"type":"streamable-http","url":"https://mcp.midgardfinance.com/mcp"}]},"_meta":{"io.modelcontextprotocol.registry/official":{"status":"active","statusChangedAt":"2026-10-29T23:23:25.288578Z","publishedAt":"2026-10-29T23:23:25.288578Z","updatedAt":"2026-10-29T23:23:25.288578Z","isLatest":false}}},{"server":{"$schema":"https://static.modelcontextprotocol.io/schemas/2025-12-11/server.schema.json","name":"com.midgardfinance/drugs","description":"Obesity and incretin drug trials: weight loss by dose with its estimand, adverse events, catalysts","title":"Midgard Finance drug data","version":"0.1.1","websiteUrl":"https://www.midgardfinance.com/obesity/","remotes":[{"type":"streamable-http","url":"https://mcp.midgardfinance.com/mcp"}]},"_meta":{"io.modelcontextprotocol.registry/official":{"status":"active","statusChangedAt":"2026-10-30T06:07:27.922806Z","publishedAt":"2026-10-30T06:07:27.922806Z","updatedAt":"2026-10-30T06:07:27.922806Z","isLatest":true}}}],"metadata":{"count":2}}